abrdn Life Sciences Investors
HQL
50 hedge funds and large institutions have $38.3M invested in abrdn Life Sciences Investors in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 49 → 50 (+1)
0.99% less ownership
Funds ownership: 12.51% → 11.52% (-0.99%)
12% less capital invested
Capital invested by funds: $43.4M → $38.3M (-$5.09M)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$1.29M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$571K |
| 3 |
BTS
BB&T Securities
Richmond,
Virginia
|
+$400K |
| 4 |
UR
USCA RIA
Houston,
Texas
|
+$354K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.6M |
| 2 |
DA
Doliver Advisors
Houston,
Texas
|
-$1.14M |
| 3 |
LPL Financial
San Diego,
California
|
-$937K |
| 4 |
Citigroup
New York
|
-$834K |
| 5 |
AIG
American International Group
New York
|
-$632K |
HQL Hedge Fund Activity: Q2 2016 in Review
50 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2016, worth a combined $38.3M — down 12% from $43.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new HQL positions and 7 closed out — a net gain of 1 holder — while 15 added to existing stakes and 18 trimmed.
The largest buyer was Stifel Financial, opening a new position worth an estimated $1.29M. The largest seller was Morgan Stanley, cutting an estimated $2.6M.
- 50 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2016, up from 49 in Q1 2016.
- Funds reported $38.3M of abrdn Life Sciences Investors stock for Q2 2016, down 12% quarter-over-quarter.
- 8 funds opened new abrdn Life Sciences Investors positions in Q2 2016 and 7 closed out, a net change of +1 holder.
- The largest abrdn Life Sciences Investors buyer in Q2 2016 was Stifel Financial, an estimated $1.29M added.
- The largest abrdn Life Sciences Investors seller in Q2 2016 was Morgan Stanley, an estimated $2.6M sold.
Based on aggregated 13F filings for Q2 2016.